The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...
Highlighted text has been updated as of December 20, 2024. The SURMOUNT-1 trial showed that among patients with obesity, once-weekly tirzepatide reduced body weight substantially as compared to ...
Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.
Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...
Their first of the season. In a bout of undefeated Idaho boys basketball programs, the Bonners Ferry Badgers beat the Bengals ...
Jastreboff A, Aronne L, Ahmad N, et al. (2022) Tirzepatide once weekly for the treatment of obesity. New Eng J Med 387: 205–16 (SURMOUNT-1) Garvey W, Frias J, Jastreboff A, et al. (2023) Tirzepatide ...
Korean auto giant logs record 1.7 million cars sold in US last year Hyundai Motor Group Executive Chair Chung Euisun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback